Rifaximin versus nonabsorbable disaccharides in the management of hepatic encephalopathy: a meta-analysis.
about
Rifaximin for people with hepatic encephalopathyEvaluation and Management of Hepatic Encephalopathy: Current Status and Future DirectionsManagement of overt hepatic encephalopathyCirrhosis and its complications: evidence based treatment.Microbiota-liver axis in hepatic disease.Rifaximin pharmacology and clinical implications.Hepatobiliary Quiz (Answers)-14 (2015).Impact of pretransplant hepatic encephalopathy on liver posttransplantation outcomes.Pathogenesis and management of alcoholic liver cirrhosis: a review.High prevalence of antibiotic-resistant bacterial infections among patients with cirrhosis at a US liver center.Management and treatment of patients with cirrhosis and portal hypertension: recommendations from the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program.Pharmacotherapy of hepatic encephalopathy in cirrhosis.Rifaximin vs. conventional oral therapy for hepatic encephalopathy: a meta-analysis.Disaccharides in the treatment of hepatic encephalopathy.Update on management of patients with overt hepatic encephalopathy.Recent insights into the pathogenesis of hepatic encephalopathy and treatments.Pathophysiology, diagnosis, and management of hepatic encephalopathy.Management in acute liver failure.Management of covert hepatic encephalopathy.Rifaximin for the treatment of diarrhea-predominant irritable bowel syndrome.Hepatic encephalopathy in dogs and cats.Small-for-Size Syndrome: Bridging the Gap Between Liver Transplantation and Graft Recovery.Hepatic encephalopathy associated with cancer or anticancer therapy.Rifaximin therapy and hepatic encephalopathy: Pros and cons.When to use antibiotics in the cirrhotic patient? The evidence base.Rifaximin for the treatment of hepatic encephalopathy.Gut instinct: rifaximin for the prevention of hepatic encephalopathy.A randomized, double-blind, controlled trial comparing rifaximin plus lactulose with lactulose alone in treatment of overt hepatic encephalopathy.
P2860
Q24187627-80362322-F98F-47B2-87F3-0CB82E3311E0Q26744689-C6F62BD5-F773-4CAC-A6A8-A79855EC7529Q26830789-73245853-B1D5-4DB1-943C-C9584DB95939Q33594931-75276A20-0211-4EF1-9864-6FE270831EEDQ33855414-0940879A-C78F-441F-96B2-37B0C9EC6CCCQ34607677-D96DD2DD-0AAB-4139-8B52-1594154ABE13Q35818316-B6164D48-29CB-44AC-A42B-518943C69AABQ37353473-E9D4B80F-A140-472E-9F6B-6207827969B1Q37355613-4DC53E48-3D88-44A8-A730-ECE7FCB6F1C1Q37478838-BFF44758-3616-400A-9632-B451CB8350DDQ37489472-33635A97-D6B0-4475-A0A6-B373D42A5014Q37729173-1C7A8016-5637-428E-85C7-60DC43A5A377Q37988849-D7435D72-414C-4CA9-B32C-0F11208F17B2Q38086120-F94503DA-A925-47B6-82BE-6DDE01398ED7Q38129187-7A44FF8E-404A-4385-A628-87DFA49B0500Q38162913-6FEE3224-AF4F-4B3B-9868-96AB05545170Q38258622-B3283651-6F07-465B-9951-BE5CC0B38E40Q38515260-613C85DB-1B9D-47C9-A933-116A453324F0Q38515281-817FEC64-A19E-456B-90EA-8044C7FC160CQ38692607-D947F7E0-9963-473B-9149-6501FC4E8A09Q38802895-B291ABD4-B9F8-4362-82D7-B490F29789B1Q40113551-2A264186-E215-44D6-BB83-7239628B7A40Q41111818-D29A2ED2-372A-4382-A807-AD7D315A4039Q42324150-C3E2E37D-9759-4FC5-9F66-73555577504FQ42406057-A67D1AD8-F1F9-4A7D-A661-530CF0628560Q42792218-7272C18E-62F7-4537-A98B-A1A15570B4CBQ42947240-68202341-FB2E-49F8-8985-E13087B1CEAEQ51222196-2F281A38-4CED-4972-AC50-54D4B60D6AFB
P2860
Rifaximin versus nonabsorbable disaccharides in the management of hepatic encephalopathy: a meta-analysis.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
Rifaximin versus nonabsorbable ...... cephalopathy: a meta-analysis.
@en
Rifaximin versus nonabsorbable ...... cephalopathy: a meta-analysis.
@nl
type
label
Rifaximin versus nonabsorbable ...... cephalopathy: a meta-analysis.
@en
Rifaximin versus nonabsorbable ...... cephalopathy: a meta-analysis.
@nl
prefLabel
Rifaximin versus nonabsorbable ...... cephalopathy: a meta-analysis.
@en
Rifaximin versus nonabsorbable ...... cephalopathy: a meta-analysis.
@nl
P2093
P1476
Rifaximin versus nonabsorbable ...... ncephalopathy: a meta-analysis
@en
P2093
Liu-Ming Jiang
Qian Jiang
Xue-Hua Jiang
Yong-Ping Chen
P304
P356
10.1097/MEG.0B013E328302F470
P577
2008-11-01T00:00:00Z